Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Levin, Schriewer"'
Autor:
Kerstin Schütze, Katharina Petry, Julia Hambach, Niklas Schuster, William Fumey, Levin Schriewer, Jana Röckendorf, Stephan Menzel, Birte Albrecht, Friedrich Haag, Catelijne Stortelers, Peter Bannas, Friedrich Koch-Nolte
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
CD38 is overexpressed by multiple myeloma cells and has emerged as a target for therapeutic antibodies. Nanobodies are soluble single domain antibody fragments derived from the VHH variable domain of heavy chain antibodies naturally occurring in came
Externí odkaz:
https://doaj.org/article/73386a564c9a465d8f987c717ce73431
Autor:
Peter Bannas, Timon Hansen, Nicolaus Kröger, Björn Rissiek, Katharina Petry, Friedrich Koch-Nolte, Mascha Binder, Boris Fehse, Julia Koenigsdorf, Levin Schriewer, Birte Albrecht, William Fumey, Jana Larissa Röckendorf, Francis Ayuk, Kerstin Schütze, Gunter Schuch, Friedrich Haag, Stephan Menzel, Gerhard Adam, Hans O. Pinnschmidt, Kristoffer Riecken, Joanna Schmid, Natalie Baum, Julia Hambach
Publikováno v:
Theranostics
Rationale: CD38 is a target for the therapy of multiple myeloma (MM) with monoclonal antibodies such as daratumumab and isatuximab. Since MM patients exhibit a high rate of relapse, the development of new biologics targeting alternative CD38 epitopes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7881d2eff2b38fc8430f0a053bf8b118
https://pubmed.ncbi.nlm.nih.gov/32194826
https://pubmed.ncbi.nlm.nih.gov/32194826
Autor:
William, Fumey, Julia, Koenigsdorf, Valentin, Kunick, Stephan, Menzel, Kerstin, Schütze, Mandy, Unger, Levin, Schriewer, Friedrich, Haag, Gerhard, Adam, Anna, Oberle, Mascha, Binder, Ralf, Fliegert, Andreas, Guse, Yong Juan, Zhao, Hon, Cheung Lee, Fabio, Malavasi, Fernando, Goldbaum, Rob, van Hegelsom, Catelijne, Stortelers, Peter, Bannas, Friedrich, Koch-Nolte
Publikováno v:
Scientific Reports
The cell surface ecto-enzyme CD38 is a promising target antigen for the treatment of hematological malignancies, as illustrated by the recent approval of daratumumab for the treatment of multiple myeloma. Our aim was to evaluate the potential of CD38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dcb9f3bca31cf59f02019d43ed7cb558
https://pubmed.ncbi.nlm.nih.gov/29084989
https://pubmed.ncbi.nlm.nih.gov/29084989
Autor:
Friedrich Koch-Nolte, Ralf Fliegert, Kerstin Schütze, Mandy Unger, Friedrich Haag, Valentin Kunick, Fernando Alberto Goldbaum, Andreas H. Guse, Fabio Malavasi, William Fumey, Peter Bannas, Hon Cheung Lee, Rob van Hegelsom, Levin Schriewer, Yong Juan Zhao, Stephan Menzel, Anna Oberle, Gerhard Adam, Julia Koenigsdorf, Mascha Binder, Catelijne Stortelers
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
The cell surface ecto-enzyme CD38 is a promising target antigen for the treatment of hematological malignancies, as illustrated by the recent approval of daratumumab for the treatment of multiple myeloma. Our aim was to evaluate the potential of CD38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4df67fb921991a528aa6a4feae0aaea2
http://hdl.handle.net/2318/1654403
http://hdl.handle.net/2318/1654403
